Fubio focuses on the research and development and clinical transformation of gene delivery vector products, and rapidly modifies more than 10 Viral vectors based on the Viral Matrix Platform technology platform. Porton Advance has established an end-to-end viral vector CDMO platform to meet the needs of virus production services from IIT, IND, clinical to commercialization stages. Both parties will leverage their respective strengths to carry out cooperation on virus delivery technologies such as adenovirus, lentivirus, adeno-associated virus, and oncolytic virus, including but not limited to the research and application of innovative vectors in basic research, cell therapy, gene therapy, and vaccine development, as well as clinical and commercial promotion.
Jun Liu , the general manager of Fubio, said:“As a platform company dedicated to the "research and development and clinical transformation of gene delivery vector products", Fubio is very honored to establish a strategic partnership with Porton . Porton Advance has gained wide recognition and respect in the CDMO field of cell and gene therapy, thanks to its profound technical accumulation and rigorous and mature compliance management system. We firmly believe that through close collaboration, both sides can establish a comprehensive mechanism for sharing market resources and business coordination, deepen the degree of strategic integration, and achieve a mutually beneficial and win-win situation. We will jointly commit to providing customers with high-quality and efficient solutions covering the entire process, actively explore new opportunities in domestic and international markets, and contribute to the innovative breakthroughs and high-quality development of the cell and gene therapy (CGT) industry."
Hui Chen , the deputy general manager of and the chief financial officer of Porton Advance, said:Porton Advance adheres to a customer-centric approach and is committed to providing innovative and reliable global CDMO solutions. We are very pleased with this cooperation with Fubio. Fubio has been deeply engaged in the field of gene delivery vector services for many years. Combined with Porton Advance rich experience and resources in the CDMO field of cell and gene therapy, it will further enhance the service capabilities and operational efficiency of both parties, create greater value for customers, and promote the development process of cell and gene therapy drugs. "Let good medicine reach the public earlier."
About Porton Advance
Porton Advance was established in December 2018. Based in Suzhou and relying on the listed company - porton Co., LTD. (stock code: 300363), it provides one-stop service solutions for the entire life cycle of gene and cell therapy drugs, from preclinical research to market launch, to global customers.
Porton Advance has established CRO and CDMO platforms covering plasmids, viral vectors, cell therapy, gene therapy, nucleic acid therapy, etc. It has a total R&D and production base area of over 20,000 square meters, 10 viral vector production lines, 12 GMP cell therapy production lines (including 2 positive production workshops), and over a hundred clean workshops. Up to now, Porton Advance has helped its clients obtain 18 clinical approvals worldwide, covering countries such as China, the United States, and New Zealand. There are already 5 Phase I /II cell therapy projects in clinical trials, and it has successfully assisted multiple overseas projects in transitioning to China.
We are committed to a customer-centric approach, providing outstanding global, end-to-end CDMO services to our clients, and enabling good medicines to reach the public earlier.
About Fubio Biotechnology
Fubio (Suzhou) Biotechnology Co., Ltd. was established in 2017. As a high-tech enterprise deeply engaged in the core fields of gene vector research and development and cell and gene therapy, We focus on providing CRO services such as gene therapy vector development, gene function research, drug target and efficacy research for enterprises in multiple fields including life sciences, in vitro diagnostics (IVD), vaccine research and development, and cell and gene therapy (CGT). We are committed to providing customers with one-stop virus products and services ranging from basic research to clinical transformation, promoting the transformation of clinical products, and continuously empowering the development of the industry.
The company has a research and development production base of over 3,500 square meters, gathering a team of "virus modification technology experts", and mastering the modification technologies and production capabilities of over 30 types of pseudovirus vectors such as LVs, Adv, and AAV. With solid technical expertise and rich experience, the team has, in the field of oncolytic viruses, leveraged its leading platform modification technology and unique process development advantages to facilitate the smooth entry of three virus/oncolytic virus projects into the IIT stage, earning high recognition from clients.
We have always adhered to the service spirit of "quality, innovation, collaboration and win-win", assisting in the discovery of gene therapy drugs and pharmaceutical research, accelerating the transformation of clinical products, and contributing to the cause of human health.
Official Account
Video Account
